AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,546 Increased By 137.4 (1.85%)
BR30 24,809 Increased By 772.4 (3.21%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)

LONDON: The fallout over the AstraZeneca jab persisted Thursday with several countries halting its use among younger people, as nations raced to secure much-needed vaccines in the face of fresh virus surges.

Europe’s medicines regulator said this week the AstraZenea vaccine could cause very rare blood clots among some recipients, prompting a cascade of countries to pull the plug on giving it to people under a certain age.

Britain sought Thursday to quell fears over the jab, saying the potential side effects were extremely rare — and the risk of getting seriously sick from Covid-19 was far greater. The furore over the jab comes as a number of countries battle mounting caseloads and deaths, more than a year into the pandemic that has killed almost 2.9 million people worldwide and ravaged the global economy.

Australia and the Philippines became the latest countries to restrict the use of AstraZeneca to older populations, joining several others, including Spain, Italy, France, Germany and Canada that took the decision earlier.

“It has not been our practice to jump at shadows, it has not been our practice to take unnecessary precautions,” Australian Prime Minister Scott Morrison said in announcing the measure. “We’ve been taking the necessary precautions based on the best possible medical advice.”

The decision came after the European Medicines Agency said Wednesday that blood clots should be listed as a “very rare” side effect of the jab, though it did not say any particular groups were at greater risk. Britain said it would offer people under 30 “alternative” vaccines to AstraZeneca — the country has also approved Pfizer and Moderna jabs — but on Thursday sought to reassure people about getting inoculated. “The vaccines are safe, and if you want to have the Pfizer vaccine or Moderna vaccine instead then that is fine,” Health Secretary Matt Hancock told the BBC. “Covid is a horrible disease and long Covid affects people in their 20s just as much it seems as any other age group and can have debilitating side effects that essentially ruin your life.”

AstraZeneca has been dogged by controversy since it was rolled out — first banned by some governments for older people over lack of data, then banned outright over clot fears. It is stored at a warmer temperature and billed as the vaccine of choice for poorer countries since it can be transported more readily than some of its counterparts. It has already been administered in some 111 countries — more than its competitors Pfizer/BioNTech and Moderna put together — according to an AFP database from official sources.

The Covax programme, which provides vaccine doses to poorer countries, was unequivocal.

More than 700 million people across India were facing coronavirus vaccine shortages after stocks dried up, even as the country saw a record 126,000 new infections in the past 24 hours.

And Indonesia said the delivery of over 100 million AstraZeneca doses could be delayed because of export restrictions in India — which produces the jab — and company supply holdups.

Comments

Comments are closed.